• 한국정보처리학회:학술대회논문집
• /
• 한국정보처리학회 2013년도 추계학술발표대회
• /
• pp.230-232
• /
• 2013

본 논문에서는 실내 음영지역에서 사용되는 모바일 와이맥스의 펨토셀 기지국(WFAP; WiMAX Femtocell AP)에 대한 성능을 분석하였다. 시뮬레이션을 통해 와이맥스 펨토셀 기지국의 패킷에러율(PER), Outage, throughput을 확인하였다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제22권3호
• /
• pp.321-329
• /
• 2018

It was recently reported that the $C_{max}$ and AUC of rosuvastatin increases when it is coadministered with telmisartan and cyclosporine. Rosuvastatin is known to be a substrate of OATP1B1, OATP1B3, NTCP, and BCRP transporters. The aim of this study was to explore the mechanism of the interactions between rosuvastatin and two perpetrators, telmisartan and cyclosporine. Published (cyclosporine) or newly developed (telmisartan) PBPK models were used to this end. The rosuvastatin model in Simcyp (version 15)'s drug library was modified to reflect racial differences in rosuvastatin exposure. In the telmisartan-rosuvastatin case, simulated rosuvastatin $C_{maxI}/C_{max}$ and $AUC_I/AUC$ (with/without telmisartan) ratios were 1.92 and 1.14, respectively, and the $T_{max}$ changed from 3.35 h to 1.40 h with coadministration of telmisartan, which were consistent with the aforementioned report ($C_{maxI}/C_{max}$: 2.01, $AUC_I/AUC$:1.18, $T_{max}:5h{\rightarrow}0.75h$). In the next case of cyclosporine-rosuvastatin, the simulated rosuvastatin $C_{maxI}/C_{max}$ and $AUC_I/AUC$ (with/without cyclosporine) ratios were 3.29 and 1.30, respectively. The decrease in the $CL_{int,BCRP,intestine}$ of rosuvastatin by telmisartan and cyclosporine in the PBPK model was pivotal to reproducing this finding in Simcyp. Our PBPK model demonstrated that the major causes of increase in rosuvastatin exposure are mediated by intestinal BCRP (rosuvastatin-telmisartan interaction) or by both of BCRP and OATP1B1/3 (rosuvastatin-cyclosporine interaction).

• 한국인터넷방송통신학회논문지
• /
• 제16권1호
• /
• pp.253-262
• /
• 2016

본 논문은 경제급전 최적화 문제에 균형-교환 방법을 제안하였다. 제안된 알고리즘은 모든 발전기를 가능한한 밸브지점으로 운영한다고 가정한다. 초기치로 최대 발전량 $P_i{\leftarrow}P_i^{max}$로 설정하고, 각 발전기의 밸브지점 $v_k$까지 발전량을 감소시켰을 때의 평균 발전단가 $c_i=\frac{F(P_i)-F(P_{iv_k})}{(P_i-P_{iv_k})}$가 최대가 되는 $_{max}c_i$ 발전기 i의 발전량을 밸브지점 발전단가 $P_{iv_k}$로 감소시켰으며, ${\Sigma}P_i-P_d$ > 0이면 $c_i=F(P_i)-F(p_i-1)$의 $_{max}c_i$ 발전기 발전량을 $P_i{\leftarrow}P_i-1$로 감소시켜 ${\Sigma}P_i=P_d$의 균형을 맞추었다. 다음으로, $_{min}\{_{max}(P_i-P_i^{min}),\;_{max}(P_i^{max}-P_i)\}$>${\alpha}{\geq}10$의 범위에 대해 "-10" 간격으로 감소시키는 성인걸음법으로, 10>${\alpha}{\geq}1$ 범위에 대해서는 "-1"의 아기걸음법으로, $P_i=P_i{\pm}{\alpha}$에 대한 $_{max}[F(P_i)-F(P_i-{\alpha})]$>$_{min}[F(P_j+{\alpha})-F(P_j)]$, $i{\neq}j$이면 $P_i=P_i-{\alpha}$, $P_j=P_j+{\alpha}$로 발전량을 교환하는 방법으로 최적화를 수행하였다. 다음으로 ${\alpha}=\text{0.1, 0.01, 0.001, 0.0001$에 대해 미세한 교환을 수행하였다. 동적 경제급전 문제의 시험 사례에 제안된 알고리즘을 적용한 결과 기존의 휴리스틱 알고리즘 최적화 발전비용을 크게 감소시켜 경제적인 이익을 극대화 시켰다.

• 한국안광학회지
• /
• 제5권1호
• /
• pp.43-48
• /
• 2000

Polarizer와 Analyzer의 Rotation 각에 의해 광의 luminance를 조절할 수 있다. Contrast Sensitivity에 대응한 luminance 값 $L_{max}$, $L_{min}$은 평균 luminance($L_m$)의 회전각 ${\theta}_m$ 최대 진폭과 최소 진폭에 대응하는 회전각 (${\theta}_{max}$, ${\theta}_{min}$)로 부터 구할 수 있다. $$L_{max}=I(0)e^{-2at}{\cdot}cos^2{\theta}_m(1+C_s^{-1})$$ $$L_{min}=I(0)e^{-2at}{\cdot}cos^2{\theta}_m(1-C_s^{-1})$$ 평균 luminance($L_m$)의 회전각 ${\theta}_m$과 측정할 Contrast Sensitivity($C_s$)로부터 polarizer와 analyzer의 회전각(${\theta}_{max}$, ${\theta}_{min}$)을 얻었다. $${\theta}_{max}=cos^{-1}[cos{\theta}_m{\cdot}(1+C_s^{-1})^{1/2}]$$ $${\theta}_{min}=cos^{-1}[cos{\theta}_m{\cdot}(1-C_s^{-1})^{1/2}]$$.

• Biomolecules & Therapeutics
• /
• 제9권4호
• /
• pp.285-290
• /
• 2001

Bioequivalence of two acetyl-1-carnitine tablets, test product (Carnitile tablet: Hanmi Pharm. Co., Ltd.) and reference product (Nicetil $e^{R}$ tablet: Dong-A Pharm. Co., Ltd.), was evaluated according to the guide- lines of Korea Food and Drug Administration (KFDA). Twenty-six healthy volunteers were divided randomly into two groups and administered the drug orally at the dose of 500 mg as acetyl-1-carnitine in a 2$\times$2 crossover study. Blood samples were taken at predetermined time intervals for 12 hours and the plasma concentration of acetyl-1-carnitine was determined using HPLC by derivatization with p-bromophenacyl bromide. The pearmacokinetic parameters (AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$) were calculated and ANOVA was utilized for the statistical analysis of parameters. The apparent differences of these parameters between two drugs were less than 20% (i.e., 1.26,-5.08 and 8.59% for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). The powers (1-$\beta$) for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, and Tmax were over 0.9. Minimal detectable difference ($\Delta$) at $\alpha$=0.05, 1-$\beta$=0.8 were less than 20% (i.e.,7.31, 14.88 and 11.77% for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). The confidence intervals ($\delta$) for these parameters were also within $\pm$ 20% (i.e.,-3.03$\leq$$\delta$$\leq$5.54, -13.80$\leq$$\delta$$\leq$3.64 and 1.69$\leq$$\delta$$\leq$15.48 for AU $C_{0-}$12h/ $C_{max}$ and $T_{max}$, respectively). These results satisfied the criteria of KFDA guideline for bioequivalence, indicating Carnitile bioequivalent to Nicetil $e^{R}$ .TEX>$^{R}$ .> R/ . R/ .

• Biomolecules & Therapeutics
• /
• 제7권1호
• /
• pp.59-65
• /
• 1999

A bioequivalence study of the Dong Wha Cisapril tablets(Dong Wha Pharm. Ind. Co., Ltd.) to the Prepulsid tablets(Janssen Korea Ltd.), formulations of cisapride, was conducted. Twenty four healthy Korean male subjects received each formulation at the dose of 5 mg as cisapride in a 2$\times$2 crossover study. There was a 1-week washout period between the doses. Plasma concentrations of cisapride were monitored by an LC/MS method for over a period of 36 h after each administration. AUC(area under the plasma concentration- time curve from time zero to infinity) was calculated by the linear trapezoidal and extrapolation method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed that there are no differences in AUC, $C_{max}$ and $T_{max}$ between the formulations. The apparent differences between the formulations in these parameters were all far less than 20% (i.e., 6.8, -6.6 and 1.8% for AUC, $C_{max}$ and $T_{max}$, respectively). Minimum detectable differences(%) at $\alpha$=0.05 and 1-$\beta$=0.8 were all less than 20% in these parameters between the formulations (i.e., 16.5, 11.4 and 16.4% for AUC, $C_{max}$ and $T_{max}$, respectively). The 90% confidence intervals for these parameters were also within 20% (i.e., -2.9~ 16.4, -13.2~0.1 and -7.8~ 11.4% for AUC, $C_{max}$ and $T_{max}$, respectively). These results satisfy the bioequivalence criteria of the Korea Food and Drug Administration (KFDA) guidelines (No. 98-51). Therefore, these results indicate that the two formulations of cisapride are bioequivalent and, thus, may be prescribed interchangeably.hangeably.y.hangeably.

• 한국컴퓨터정보학회논문지
• /
• 제17권11호
• /
• pp.189-196
• /
• 2012

본 논문은 동적 경제급전의 최적화 문제를 풀기 위해 교환 알고리즘을 제안하였다. 제안된 알고리즘은 첫 번째로, 발전단가 $C_i^{max}/P_i^{max}$가 비싼 발전기는 가동을 중지시키는 개념을 도입하여 총 요구량 $P_d$와 총 발전량 ${\Sigma}P_i$의 균형을 맞추었다. 다음으로 발전량을 $P_i=P_i{\pm}{\Delta}$, (${\Delta}$=1.0, 0.1, 0.01, 0.001)에 대해 $_{max}[F(P_i)-F(P_i-{\Delta})]$ > $_{min}[F(P_j+{\Delta})-F(P_j)]$, $i{\neq}j$이면 $P_i=P_i-{\Delta}$, $P_j=P_j+{\Delta}$로 발전량을 교환하는 방법을 적용하였다. 동적 경제급전 문제의 시험사례에 제안된 알고리즘을 적용한 결과 기존의 휴리스틱 알고리즘 최적화 발전비용을 크기 감소시켜 경제적인 이익을 극대화 시켰다.

• 한국패류학회지
• /
• 제28권4호
• /
• pp.349-359
• /
• 2012

The purpose of this study is to compare the clearance rate (CR) and intake rate (IR) of juvenile purple clam, Saxidomus purpuratus when feeding on different unialgal diet of red tide dinoflagellates (RTDs), and to know what is the most important cell characteristic of RTDs to cause the differences in feeding parameters. Experiments were performed to measure the CR and IR of juvenile S. purpuratus as a function of algal concentration when food was either the standard food, Isochrysis galbana or one of 9 RTDs. Patterns of CR with increasing algal concentration were similar among different RTDs. The highest $C_{max}$ was observed when S. purpuratus was feeding on A. affine, while the lowest on C. polykrikoides. The patterns of IR with increasing algal concentration were also similar among different RTDs. However, there were great differences in the maximum value of IR ($I_{max}$) among different RTDs. The highest $I_{max}$ was observed when S. purpuratus was feeding on A. carterae, while the lowest on G. catenatum. Some RTDs similar in size showed different $C_{max}$. Other RTDs different in size showed similar $I_{max}$. Life form of each RTD affected significantly the $I_{max}$, which was higher for single-celled RTDs than chain-forming RTDs. There were no significant differences in feeding parameters between toxic and nontoxic RTDs. Moreover, a toxic dinoflagellate, A. carterae recorded the highest $I_{max}$ among RTDs. The most important characteristic of RTD as a factor affecting the feeding rate of S. purpuratus was life form, not size or toxicity of RTD species.

• Journal of Pharmaceutical Investigation
• /
• 제29권2호
• /
• pp.145-149
• /
• 1999

Bioequivalence of two cefixime capsules, test drug ($Cepirin^R$ capsule: Cheiljedang Corp.) and reference drug ($Suprax^R$ capsule: Dong A Pharm. Com.), was evaluated according to the guidelines of Korea Food and Drug Administration (KFDA). Sixteen healthy volunteers were divided randomly into two groups and administered the drug orally at the dose of 400 mg as cefixime in a $2{\times}2$ crossover study. There was a 1-week washout period between the administrations. Blood samples were taken at predetermined time intervals for 12 hour and the plasma concentration of cefixime was determined with a HPLC method. $AUC_{0-12hr}$ (area under the plasma concentration-time curve form time zero to 12 hour), $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were estimated from the plasma drug concentrationtime data. Analysis of variance (ANOVA) revealed no difference in $AUC_{0-12hr}$, $C_{max}$ and $T_{max}$ between the formulations. The apparent differences of these parameters between the formulations were less than 20% (i.e., 8.62, 11.10 and 0.00% for $AUC_{0-12hr}$, $C_{max}$ and $T_{max}$,respectively). The powers $(1-{\beta})$ for $AUC_{0-12hr}$ $C_{max}$ and $T_{max}$ were over 0.9. Minimal detectable difference $({\Delta})$ at ${\alpha}=0.05$, $1-{\beta}=0.8$ were less than 20% (i.e., 12.84, 11.05 and 17.99% for $AUC_{0-12hr}$, $C_{max}$ and $T_{max}$, respectively). The 90% confidence intervals $({\delta})$ for these parameters were also within ${\pm}20%$ (i.e., $-0.53{\le}{\delta}{\le}17.76$, $3.23{\le}{\delta}{\le}18.97$ and $-12.81{\le}{\delta}{\le}12.81$ for $AUC_{0-12hr}$, $C_{max}$ and $T_{max}$, respectively). These results satisfied the criteria of KFDA guideline for bioequivalence, indicating the two formulations of cefixime were bioequivlent.

• Journal of Pharmaceutical Investigation
• /
• 제30권1호
• /
• pp.55-59
• /
• 2000

Bioequivalence of two cisapride tablets, test drug ($Cisple^{\circledR}$ tablet: Hanmi Pharm Co., Ltd.) and reference drug ($Prepulsid^{\circledR}$ tablet: Janssen Pharm. Co., Ltd.), was evaluated according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty two healthy male volunteers were divided randomly into two groups and administered the drug orally at the dose of 10 mg as cisapride in a $2{\times}2$ crossover study. There was a week washout period between administrations. Blood samples were taken at predetermined time intervals for 36 hr and the plasma concentration of cisapride was determined by a HPLC method. $AUC_{0-36hr}$ (area under the plasma concentration-time curve from time zero to 36 hr), $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were estimated from the plasma drug concentration-time data. Analysis of variance (ANOVA) revealed no difference in $AUC_{0-36hr},\;C_{max}\;and\;T_{max}$ between two products. The apparent differences of these parameters between two products were less than 20% (i.e., 5.38, 6.17 and 0.00% for $AUC_{0-36hr},\;C_{max}\;and\;T_{max},$ respectively). The powers $(1-\beta)$ for $AUC_{0-36hr},\;C_{max}\;and\;T_{max}$ were over 0.9. Minimal detectable differences $(\Delta)$ at ${\alpha}=0.05,\;1-{\beta}=0.8$ were less than 20% (i.e. 17.67, 14.84 and 19.72% for $AUC_{0-36hr},\;C_{max}\;and\;T_{max},$ respectively). The 90% confidence intervals $(\delta)$ for these parameters were also within ${\pm}20%$ $(i.e.\;-4.97\;{\le}{\delta}{\le}\;15.73,\;-2.53{\le}{\delta}{\le}\;14.86\;and\;-11.55{\le}{\delta}{\le}\;11.55$ for $AUC_{0-36hr},\;C_{max}\;and\;T_{max},$ respectively). These results satisfied the criteria of KFDA guidelines for bioequivalence, indicating the two tablets of cisapride were bioequivalent.